MARLBOROUGH, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that the company will present results from a novel same-section, spatial multiomic study at the Advances in Genome Biology and Technology (AGBT) Annual Meeting being held in Hollywood, Florida from February 6-9, 2023. Leveraging the high-speed imaging platform, PhenoCycler®-Fusion, company scientists to showcase how imaging both RNA and protein biomarkers simultaneously, in a single tissue section, can give a more complete picture of tumor biology.
Protein and RNA biomarkers play complementary roles in defining cell phenotypes and cell states, respectively, in a tissue sample. Proteins are the key effectors of cell function and detecting cell surface protein markers can serve as a ground truth for cell identity. RNA markers such as cytokines and chemokines can provide an insight into signaling pathways that result in changes in cell states, arising from interactions within the tumor microenvironment. Measuring both analytes within the same tissue can give researchers an accurate picture of tumor progression and response to therapy.
First unveiled at the AGBT Annual Meeting in 2022, the company’s RNA chemistry was combined with the company’s industry-leading proteomics offering in a novel multiomic study featuring 46 samples, 23 tissue types and simultaneous detection of RNA and protein biomarkers from each section. The ability to scale the chemistry across multiple samples and a diversity of tissue types is a key requirement for discovering robust biomarker signatures.
The study was conducted on the PhenoCycler-Fusion System which enables rapid imaging of whole slides at single-cell resolution. In addition to the speed of imaging, the system has a proprietary file compression algorithm that can reduce file sizes from terabytes to gigabytes. This powerful combination makes it easier for researchers to scale up their studies with higher weekly throughput, while reducing data storage costs.
This new dataset will be presented at Akoya’s opening in-suite talk. Details below. To register, click here.
In Suite Talk: True Spatial Multiomics: One section, Two analytes
Date: Tuesday, February 7, 10:30 – 11:00 am ET
Speakers: Niro Ramachandran, Ph.D., Chief Business Officer, Akoya Biosciences and Julia Kennedy-Darling, Ph.D., VP Innovation, Akoya Biosciences
Venue: Exhibit Suite #313, Third Floor, Diplomat Hotel
“We are excited to highlight the breakthrough capabilities of our spatial transcriptomics chemistry and how a multiomic view of each sample can uncover a new dimension in tissue biology,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. “We are looking forward to sharing these datasets with the genomics community at AGBT.”
Additional talks and poster presentations featuring collaborators and customers are listed by date and time below:
Poster and Flash Talk: High-speed multiomic spatial phenotyping of immunotherapy responses in head and neck cancer
Presenter: Oliver Braubach, Ph.D., Akoya Biosciences
Date and Time: Tuesday, February 7, 1:30 – 3:30 PM
Poster Number: 129
Dr. Braubach will also be presenting a Flash Talk on this poster in the Grand Ballroom on Tuesday, February 7th at 11:25 AM – 11:49 AM
Poster and Flash Talk: A multiomic spatial phenotypic atlas of triple-negative breast cancer in women of African ancestry
Presenter: Jasmine Plummer, Ph.D. Director, St. Jude Center for Spatial Omics, St. Jude Children’s Research Hospital
Date and Time: Tuesday, February 7, 1:30 – 3:30 PM
Poster Number: 137
Dr. Plummer will also be presenting a Flash Talk on this poster in the Grand Ballroom on Tuesday, February 7th at 11:25 AM – 11:49 AM
Presentation: Mechanisms of metaplastic progression to adenocarcinoma revealed by high-speed multiomic spatial phenotyping of FFPE human samples
Presenter: John Hickey, Ph.D., Stanford University
Date and Time: Tuesday, February 7, 7:50 – 8:10 PM
Concurrent Session: Cancer, Grand Ballroom
Presentation: High-speed multiomic spatial phenotyping of FFPE human cohorts to dissect mechanisms of environmental-conditioned metastasis
Presenter: Julia Kennedy-Darling, Ph.D., Akoya Biosciences; presenting on behalf of Garry Nolan, Ph.D., Stanford University
Date and Time: Tuesday, February 7, 8:30 – 8:50 PM
Concurrent Session: Cancer, Grand Ballroom
Poster: Rapid whole-slide spatial analysis of FFPE tissues with true multiomic panels enables the discovery of key cellular niches
Author: Julia Kennedy-Darling, Ph.D., Akoya Biosciences
Date and Time: Wednesday, February 8, 4:45 – 6:10 PM
Poster Number: 532
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Christine Quern
(617) 650-8497
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.17 |
Daily Change: | -0.05 -1.55 |
Daily Volume: | 57,357 |
Market Cap: | US$156.920M |
November 05, 2024 August 05, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB